News

AKL and APPA in the Press



Recently there have been various press reports on AKL's collaboration with Liverpool University on the clinical development of APPA. There has been coverage in both industry and mainstream press with Prof Rob Moots and Prof Steven Edwards being quoted extensively.     Pharma Times: Liverpool Uni leads clinical trial of promising osteoarthritis drug Drug Development Technology: Liverpool and AKL collaborate to evaluate APPA for osteoarthritis Daily Express: New treatment hailed as a 'new dawn' for arthritis sufferers Daily Mail: From Peonies to ease arthritic knees to...
Read More

Liverpool University Press Release



Clinical trial for new innovative Osteoarthritis drug The University of Liverpool, in partnership with AKL Research and Development Ltd, is to lead on a clinical trial to test a potential new drug treatment for osteoarthritis. Osteoarthritis (OA) is the most common type of arthritis in the UK, affecting more than eight million people*, and is the leading cause of joint pain and stiffness in older people. As part of their research and development programme, AKL identifies promising phytochemicals, found in natural products, which are capable of being synthesized. Trials have identif...
Read More

Summary of Effects of APPA on Neutrophils



AKL, in collaboration with the University of Liverpool, were accepted for a presentation at the 2016 OARSI (Osteoarthritis Research Society International) Congress Summary of Effects of APPA on Human Neutrophils Function APPA is a synergistic combination of 2 synthetic anti-inflammatory molecules. APPA has shown efficacy in several animal models of osteoarthritis, decreasing pain and meniscal cartilage damage. Its efficacy is thought to be due to the effects of the constituent components on various levels of regulation of the transcription factor, NF-κB but as we show here also has eff...
Read More

APPA has completed required preclinical toxicology studies successfully



We believe APPA is now ready to apply for regulatory approval to start formal human trials now that required preclinical toxicology studies have been completed. There is a considerable body of evidence behind the efficacy, safety, tolerability and mode of action of APPA. Consistent with data in the public domain, the studies undertaken indicate that the toxicity potential of orally administered APPA is low. In vitro genotoxicity panel with a clean outcome for both molecules. APPA also completed in vivo preclinical toxicology studies with no clinical signs of toxicity or out-of-range lab...
Read More
Page 1 of 212